{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:54:19Z","timestamp":1791222859861,"version":"4.1.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T00:00:00Z","timestamp":1471392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0160087","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T14:43:13Z","timestamp":1471444993000},"page":"e0160087","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-1808","authenticated-orcid":true,"given":"Jiangzhou","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaomin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e97262","DOI":"10.1371\/journal.pone.0097262","article-title":"Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population","volume":"9","author":"LF Lopez-Cortes","year":"2014","journal-title":"Plos One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2008.05.006","article-title":"New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists","volume":"57","author":"A Hughes","year":"2008","journal-title":"J Infect"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1517\/14656566.2012.742506","article-title":"New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data","volume":"13","author":"D Jayaweera","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2174\/092986706777935069","article-title":"A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20)","volume":"13","author":"R Manfredi","year":"2006","journal-title":"Curr Med Chem"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"AR Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"B Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"V Summa","year":"2008","journal-title":"J Med Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.biopha.2014.09.013","article-title":"Newly approved integrase inhibitors for clinical treatment of AIDS","volume":"68","author":"WG Gu","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1128\/JVI.76.8.3739-3747.2002","article-title":"Human immunodeficiency virus cDNA metabolism: Notable stability of two-long terminal repeat circles","volume":"76","author":"SL Butler","year":"2002","journal-title":"J Virol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"DJ Hazuda","year":"2000","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"P German","year":"2010","journal-title":"J Acquir Immun Defic Syndr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/mt.2012.6","article-title":"Lens Epithelium-derived growth factor\/p75 qualifies as a target for HIV gene therapy in the NSG mouse model","volume":"20","author":"S Vets","year":"2012","journal-title":"Mol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-013-1590-9","article-title":"Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment","volume":"70","author":"S Weller","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"JJ Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12272-012-0406-2","article-title":"Design, synthesis, and anti-influenza viral activities of 1,3-diarylprop-2-en-1-ones: a novel class of neuraminidase inhibitors","volume":"35","author":"M Kinger","year":"2012","journal-title":"Arch Pharm Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"L Wood","year":"2008","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"12","author":"JP Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1467-985X.2004.298_3.x","article-title":"Statistical rules of thumb","volume":"167","author":"QL Burrell","year":"2004","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.3511","article-title":"Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells","volume":"28","author":"G Rucker","year":"2009","journal-title":"Stat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"F Raffi","year":"2014","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"JJ Eron","year":"2010","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"JM Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/QAD.0b013e328348065a","article-title":"Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies","volume":"25","author":"JK Rockstroh","year":"2011","journal-title":"AIDS"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO Trial","volume":"49","author":"Y Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"B Taiwo","year":"2011","journal-title":"AIDS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/00365541003621502","article-title":"Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients","volume":"42","author":"F Caby","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"C Cohen","year":"2011","journal-title":"AIDS"},{"key":"ref32","first-page":"730","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"380","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"JR Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"A Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/AAC.05694-11","article-title":"Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy","volume":"56","author":"J Ananworanich","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"D Armenia","year":"2012","journal-title":"J Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/ijms14035013","article-title":"Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in northeastern South Africa","volume":"14","author":"PO Bessong","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2013.10.013","article-title":"Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study","volume":"43","author":"A Capetti","year":"2014","journal-title":"Int JAntimicrob Agents"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"JJ Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.coviro.2012.08.005","article-title":"The future of integrase inhibitors of HIV-1","volume":"2","author":"I Malet","year":"2012","journal-title":"Curr Opin Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/v2071347","article-title":"Resistance to integrase inhibitors","volume":"2","author":"M Metifiot","year":"2010","journal-title":"Viruses"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-4690-6-25","article-title":"Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors","volume":"6","author":"E Serrao","year":"2009","journal-title":"Retrovirology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"DA Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012","volume":"58","author":"CB Hurt","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0160087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:45:28Z","timestamp":1540284328000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0160087"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0160087","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,17]]}}}